Screener
Tango Therapeutics TNGX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $2,430 | $1,182 |
| Accrued expenses and other current liabilities | 9,068 | 17,759 |
| Operating lease liabilities | 2,832 | 2,738 |
| Total current liabilities | 14,330 | 21,679 |
| Operating lease liabilities, net of current portion | 29,956 | 30,832 |
| Total liabilities | 44,286 | 52,511 |
| Commitments and contingencies (Note 7) | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | — | — |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's total current liabilities?
- Tango Therapeutics (TNGX) reported total current liabilities of $14.33M in Q1 2026.
- How has Tango Therapeutics's total current liabilities changed year-over-year?
- Tango Therapeutics's total current liabilities decreased by 60.1% year-over-year, from $35.92M to $14.33M.
- What is the long-term trend for Tango Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Tango Therapeutics's total current liabilities has grown at a -11.9% compound annual growth rate (CAGR), from $40.92M to $21.68M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Tango Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude